Name: Aft Pharmaceuticals (AFP) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

AFP

Pharmaceuticals, Biotechnology & Life Sciences

Aft Pharmaceuticals

Short interest: 0.00%; 0.00 pp 30d; as of 6 Aug 2021
Reported shorts: 667
Shares on issue: 104.679M

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About Aft Pharmaceuticals

AFT Pharmaceuticals is a dynamic multinational company that specializes in developing and in-licensing a broad spectrum of pharmaceutical products. They serve multiple distribution channels, including over-the-counter medications, prescription drugs, and hospital treatments. The company's unique value proposition lies in its extensive product portfolio and strategic partnerships, enhancing its market position within the pharmaceutical industry.

Company profile →

Aft Pharmaceuticals (ASX:AFP) has 0.00% of its shares on issue reported as short positions as of 6 Aug 2021, or about 667 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. AFP is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.

Strategy fit

How each stock picker strategy reads AFP today

Zanger BreakoutWatchScore 41rank 205 of 1942
CAN SLIMWatchScore 37rank 178 of 1541
Minervini Trend TemplateWatchScore 61rank 184 of 1716
Crowded-Short BreakoutWatchScore 12rank 767 of 1500
Quality compoundersWatchScore 34rank 318 of 1669

Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

AFP fundamentals

In the year to 31 Mar 2026, Aft Pharmaceuticals (ASX:AFP) recorded revenue of NZ$251.2M and net profit after tax of NZ$14.7M. A year earlier it recorded revenue of NZ$205.5M and net profit after tax of NZ$12.0M. Year-on-year growth: revenue +22.2% (FY), EPS +27.3% (TTM). Net margin 5.9%, return on equity 14.2% (FY). Figures are in NZD, the company's reporting currency; source: Yahoo Finance, as at 14 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →